Looks like ASTY news may be putting some bounce in CUR's step. Asterias cleared for stem cell trial in spinal cord injury The FDA clears Asterias Biotherapeutics (OTCPK:ASTY) to initiate a Phase 1/2a clinical trial of AST-OPC1 in patients with completed cervical spinal cord injury. The trial will assess the safety and activity of escalating doses of AST-OPC1, oligodendrocyte progenitor cells derived from human embryonic stem cells.The agency approved the next trial phase based on the results of a five-patient Phase 1 trial who had neurologically complete thoracic spinal cord injury. Each patient received a dose of 2M AST-OPC1 cells and have been followed for two to three years. No serious adverse events have been observed.The Phase 1/2a trial will involve doses up to 10x higher in patients with cervical spinal cord injury. Patient enrollment should commence in Q1 2015. The results will support a Phase 2b trial that will more thoroughly assess the safety and efficacy of AST-OPC1.The California Institute for Regenerative Medicine awarded the company a grant of $14.3M to help fund the work.
CUR.... jumped past 3.74 and could make it support.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.